Nasdaq panel grants Vivos continued listing subject to filing Q2 Form 10-Q by Aug 15, 2024

Vivos Therapeutics, Inc.

Panel granted continued listing on Nasdaq conditional on filing Form 10-Q for quarter ended June 30, 2024 by August 15, 2024.
Company must evidence stockholders' equity of at least $2.5 million in the Form 10-Q.
Exploring additional equity financing to maintain compliance with Nasdaq equity requirement.
Risk of delisting if compliance not achieved; delisting would materially harm stock price and capital access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.